Uncontrolled Asthma: Dupilumab vs. High Dose ICS

We are studying whether adding dupilumab to medium dose asthma medication helps reduce severe asthma attacks better than increasing the dose of current treatments. This trial is for adolescents and adults with uncontrolled asthma.

1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessPartially RemoteInvestigational MedicinesInjectionAllergologyPulmonology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Dupixent
Dupixent is a medicine used to treat eczema and certain asthma symptoms.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dupilumab
Dupilumab is a substance that reduces allergic inflammation to treat moderate-to-severe eczema, some asthma, and nasal polyps.
Fluticasone Propionate
Fluticasone propionate is a corticosteroid substance that reduces inflammation in the airways, nose, or skin to relieve allergy and asthma symptoms.
Salmeterol
Salmeterol is a long-acting substance that relaxes airway muscles to help people with asthma or COPD breathe more easily.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Advair

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Region Hovedstaden
208002: Lungemedicinsk Forskning
Frederiksberg, Denmark
Hvidovre Hospital
208001: Lungemedicinsk Afdeling
Hvidovre, Denmark
Lillebaelt Hospital
208003: Lungemedicinsk Forskningsenhed
Vejle, Denmark
Sponsor: Regeneron Pharmaceuticals Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.